Evaluation of Side Effects of Mitotane

University of Wuerzburg

Status: Active, not recruiting

Conditions: Adrenocortical Carcinoma

Study type: Observational

Funder types: Other

Identifiers

NCT00568139

Wue-ACC-Mitotane

Details and patient eligibility

About

Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many adverse effects are not well documented. Therefore, we are aiming at collecting data about adverse effects in patients treated with mitotane

Enrollment: 400 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Adrenocortical carcinoma
• Treatment with mitotane monotherapy as first-line therapy (in adjuvant setting or advanced disease)

Trial design

400 participants in 1 patient group

Mitotane

Description:

Patients with adrenocortical carcinoma treated with mitotane monotherapy